Otrivin spray nasal with menthol and eucalypt flavour

Riik: Armeenia

keel: inglise

Allikas: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Toimeaine:

xylometazoline (xylometazoline hydrochloride)

Saadav alates:

GlaxoSmithKline Consumer Healthcare S.A.

ATC kood:

R01AA07

INN (Rahvusvaheline Nimetus):

xylometazoline (xylometazoline hydrochloride)

Annus:

1mg/ml

Ravimvorm:

spray nasal with menthol and eucalypt flavour

Ühikuid pakis:

10ml plastic vial with metering pump

Retsepti tüüp:

OTC

Volitamisolek:

Registered

Loa andmise kuupäev:

2019-11-27

Toote omadused

GSK Consumer
Healthcare S.A.
CH-1260, Nyon, Switzerland Global Regulatory Affairs
Global Labelling &
Compliance
OTRIVIN
_ _
0.1%
MOISTURISING FORMULA (F.5)
Metered-Dose Spray 0.1% with menthol and eucalypt
Xylometazoline hydrochloride 0.1%
CORE SUMMARY OF PRODUCT CHARACTERISTICS (SMPC)
Amendment date(s):
Release date:
07 Aug 2019
Next Update date:
Number of pages:
8
Property of GSK Consumer Healthcare
S.A. Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of GSK Consumer Healthcare S.A.
CONFIDENTIAL
GSK Consumer Healthcare S.A.
Core SmPC
Page 2
Otrivin 0.1
1.
NAME OF THE MEDICINAL PRODUCT
.................................................................. 3
2.
QUALITATIVE AND QUANTITATIVE
COMPOSITION......................................... 3
3.
PHARMACEUTICAL
FORMS.....................................................................................
3
4.
CLINICAL PARTICULARS
.........................................................................................
3
4.1.
Therapeutic
indications.......................................................................................
3
4.2.
Posology and method of administration
............................................................. 3
4.3.
Contra-indications
..............................................................................................
4
4.4.
Special warnings and special precautions for use
.............................................. 4
4.5.
Interactions with other medicinal products and other forms of
interaction........ 4
4.6.
Pregnancy and lactation
......................................................................................
4
4.7.
Effects on ability to drive and use machines
...................................................... 4
4.8.
Undesirable effects
.............................................................................................
5
4.9.
Overdose
.............................................................................................................
5
5.
PHARMACOLOGIC